Navigation Links
Leading Pharma Company Selects Clinilabs to Conduct a Phase 1 Study of an Investigational Type 2 Diabetes Medication

NEW YORK, Sept. 30, 2013 /PRNewswire-iReach/ -- Clinilabs, a contract research organization that provides early-stage and specialty clinical drug development services to industry, announced today that they have begun a Phase I clinical research study of an investigational medication for Type 2 Diabetes Mellitus.  The study is being conducted to assess the safety and tolerability of multiple daily doses of the investigational medication over periods of up to 28 days.  

Diabetes has become one of the most prevalent diseases in the United States, with approximately 2 million people diagnosed each year.  The Center for Disease Control and Prevention estimates that roughly 35% of the population over the age of 20 is pre-diabetic.  For those over the age of 65, this number increases to 50%.  Clinilabs understands the growing need for treatment options in this field and is dedicated to helping sufferers combat the disease.  In response to the study award, Lead Recruiter Carrie Sorkin states: "Patients understand that clinical trials are a great way to find alternative treatment options for diabetes.  At Clinilabs, we have seen this first-hand through the great success we have had in our recruitment efforts."

Clinilabs is currently enrolling male and female volunteers, between the ages of 18 and 70, who have been diagnosed with Type 2 Diabetes Mellitus.  Any female patients interested in volunteering for this study must not be of childbearing potential. Patients must be on a stable treatment regimen for at least 4 weeks prior to screening and must have a body weight of above 45.0 kg.

Individuals in the Central New Jersey area who would like to participate can contact our dedicated call center at 212-994-4567 to prequalify.  Additional information may also be found by visiting  If you are a Physician in the New Jersey or New York area and are interested in referring patients for this trial please contact us at

About Clinilabs Inc.

Clinilabs is a full-service contract research organization (CRO) that specializes in early-phase studies, from first-in-human to proof-of-concept, with normal healthy volunteers and patient populations.  The company owns and operates two Phase I units in the US, and maintains a network of highly qualified investigator sites for multicenter Phase II studies Worldwide.  Specialty projects, including pharmacodynamic, biomarker, cardiac safety, sleep/wakefulness, metabolic, and Japanese bridging are among our strengths.  Clinilabs is recognized globally as a leading specialty CRO, offering an alternative to large CROs for specialty projects.  For more information, please visit

Media Contact: Hannah DAoust, Clinilabs, 646-215-6480,

News distributed by PR Newswire iReach:

SOURCE Clinilabs
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Leading evolutionary scientist to discuss how genome of bacteria has evolved
2. Worlds leading coral experts to gather in Australia
3. Putting plants online: 4 leading botanical gardens to create first online catalog of all plants
4. EMBO welcomes 55 leading life scientists as members
5. Leading statistician receives national citation award
6. Leading childhood asthma group supports federal asthma action plan to reduce disparities
7. BiOptix Participates in Leading Life Sciences Event BioWest 2012
8. Team including UC Riverside entomologist honored for research leading to healthier potato chips
9. Aware Enables Automated Delivery of Radiation Dose Information Through Integration With Leading Radiology Reporting System
10. Discovery of pathway leading to depression reveals new drug targets
11. Leading RSV researcher publishes work at Le Bonheur Childrens
Post Your Comments:
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... ... operations for Amgen, will join the faculty of the University of North ... adjunct professor of strategy and entrepreneurship at UNC Kenan-Flagler, with a focus on ...
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology: